Gary Anglebrandt
- Top executive: James Koziarz, president and CEO Patents in 2014: 3 Score: 139.80 Rubicon develops and manufactures biological tools for genetic testing used in drug development and diagnosis. The company has a portfolio of 12 in-force patents with issue dates ranging from 2004 to 2014, all directed toward nucleotide amplification technology. Ocean Tomo gives high marks to the entire portfolio. Those covered last year include one for "DNA amplification and sequencing using DNA molecules
↧